Editorial

SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now

Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Lewis EJ,
    2. Hunsicker LG,
    3. Bain RP,
    4. Rohde RD
    . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20):1456–1462. doi:10.1056/NEJM199311113292004
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lewis EJ,
    2. Hunsicker LG,
    3. Clarke WR,
    4. et al.
    5. Collaborative Study Group
    . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12):851–860. doi:10.1056/NEJMoa011303
    OpenUrlCrossRefPubMed
  3. ↵
    1. Brenner BM,
    2. Cooper ME,
    3. de Zeeuw D,
    4. et al.
    5. RENAAL Study Investigators
    . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869. doi:10.1056/NEJMoa011161
    OpenUrlCrossRefPubMed
  4. ↵
    1. Tsushima Y,
    2. Lansang MC,
    3. Makin V
    . The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleve Clin J Med 2021; 88(1):47–58. doi:10.3949/ccjm.88a.20088
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. American Diabetes Association
    . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 2020; 43(suppl 1):S98–S110. doi:10.2337/dc20-S009
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Garber AJ,
    2. Handelsman Y,
    3. Grunberger G,
    4. et al
    . Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 Executive Summary. Endocr Pract 2020; 26(1):107–139. doi:10.4158/CS-2019-0472
    OpenUrlCrossRef
  7. ↵
    1. de Boer I,
    2. Luiza Caramori M,
    3. Chan J,
    4. et al
    . Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020; 98(4):839–848. doi:10.1016/j.kint.2020.06.024
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wanner C,
    2. Inzucchi SE,
    3. Zinman B
    . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(18):1801–1802. doi:10.1056/NEJMc1611290
    OpenUrlCrossRefPubMed
    1. Packer M,
    2. Anker SD,
    3. Butler J,
    4. et al
    . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020 August 28; NEJMoa2022190. doi:10.1056/NEJMoa2022190
    OpenUrlCrossRef
    1. Neal B,
    2. Perkovic V,
    3. Mahaffey KW,
    4. et al
    . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7):644–657. doi:10.1056/NEJMoa1611925
    OpenUrlCrossRef
    1. Wiviott W,
    2. Raz I,
    3. Bonaca M,
    4. et al
    . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4):347–357. doi:10.1056/NEJMoa1812389
    OpenUrlCrossRefPubMed
  12. ↵
    1. Perkovic V,
    2. Jardine MJ,
    3. Neal B,
    4. et al
    . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24):2295–2306. doi:10.1056/NEJMoa1811744
    OpenUrlCrossRefPubMed
  13. ↵
    1. Heerspink HJL,
    2. Stefánsson BV,
    3. Correa-Rotter R
    . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15):1436–1446. doi:10.1056/NEJMoa2024816
    OpenUrlCrossRefPubMed
  14. ↵ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection with Empagliflozin). Identifier NCT03594110
  15. ↵
    1. Organ Procurement and Transplantation Network
    . AK OPTN/SRTR 2019 annual data report. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/
  16. ↵
    1. Bakris GL,
    2. Agarwal R,
    3. Anker SD,
    4. Pitt B,
    5. et al.
    6. for the FIDELIO-DKD Investigators
    . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020 October 23. doi:10.1056/NEJMoa2025845
    OpenUrlCrossRefPubMed
  17. ↵
    1. Heerspink PH,
    2. Parving H-H,
    3. Andress DL,
    4. et al.
    5. SONAR Committees and Investigators
    . Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393(10184):1937–1947. doi:10.1016/S0140-6736(19)30772-X
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects